Published on February 19, 2014
BOOK BY 31ST MARCH AND SAVE £300 BOOK BY 30TH APRIL AND SAVE £100 “Great conference! Well organised” Sanofi 30TH JUNE -1ST JULY SMi present their 9th annual conference on… ADMET Enhancing drug quality by ADMET optimisation in discovery 2014 The Marriott Regents Park Hotel, London, UK Conference chairs: • erry Kenna, Safety Science Adviser and Network Partner, G The Research Network • lan Wilson, Vice President, Lexicon Pharmaceuticals A Key Speakers: • atalie Gobeau, Metabolism and Pharmacokinetics, Novartis N • ietmar-Weitz, Lab Head/ADME In Vitro Systems, Sanofi-Aventis D • arah Baldwin, In Vitro DMPK Manager, GSK S • hris Powell, VP Safety Assessment, GSK C • eorg Schmitt, Head of Toxicology, Roche Pharmaceuticals G • ichard Thompson, Principal Scientist, AstraZeneca R • ranck Atienzar, Associate Director, In Vitro and In Silico Toxicology, UCB F • dina Tocoian, Senior Clinical Pharmacologist, UCB A • avid Fairman, Senior Clinical Pharmacokinetist, MedImmune D WHY ATTEND THIS EVENT: • Understand how to integrate ADME and toxicity data to enhance the prediction and understanding of drug safety in humans • Hear the latest updates on drug transporters including the evolving transporter strategies in drug development and the different roles of drug transporters in R&D • Explore the ADME properties of peptides in drug discovery • Evaluate and overcome the challenges of making an accurate human dose prediction PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS Wednesday 2nd July 2014, The Marriott Regents Park Hotel, London, UK A: Computational Approaches in ADMET B: ADME for the Medicinal Chemist Workshop Leader: Dr Nick Plant, Reader in Molecular Toxicology, University of Surrey Workshop Leader: Dr Corinne Kay, Company DIrector, Med-Simple 1.30pm - 5.30pm 8.30am - 12.30pm Sponsored by www.admet-event.com Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 BOOK BY 31ST MARCH AND SAVE £300 • BOOK BY 30TH APRIL AND SAVE £100
ADMET 2014 www.admet Day One I Monday 30th June 2014 8.30 Registration & Coffee 1.00 Networking Lunch 9.00 Chairman’s Opening Remarks Alan Wilson, Vice President, Lexicon Pharmaceuticals 2.00 Exploring the ADME properties of peptides in drug discovery • Metabolism of peptides • What in vitro metabolism studies can we employ? ADMET IN DRUG DEVELOPMENT 9.10 • LC-MS analysis of peptides in drug discovery • Absorption of peptides Role of ADMET in drug development Jørgen Olsen, Principal Scientist, Novo Nordisk • Role of ADMET in optimizing drug discovery and development • The role of good laboratory practice in non-clinical ADMET 2.40 studies • Contrasting small and large molecule ADME challenges • Optimizing the value of predictive ADMET/PK • Introduction to monoclonal antibody (mAB) PK and PKPD • Future opportunities and challenges • mAB half life modification strategies Alan Wilson, Vice President, Lexicon Pharmaceuticals 9.50 ADME for biologics, progress and challenges The challenges of making an accurate human dose prediction David Fairman, Senior Clinical Pharmacokinetist, MedImmune 3.20 Afternoon Tea • How to predict accurate PK parameters PREDICTIVE VALUE OF TOXICITY • What in vitro and in vivo tools can we use and how should we use them • Understanding the driver of efficacy 3.50 The role of non-clinical safety testing in drug research & • Dealing with active processes development and clinical safety • Understanding and appreciation of errors and their • Non-regulated and regulated areas implications • Predictive value with a focus on toxicology Peter Littlewood, Director DMPK, Vertex • Strategic approaches within the value chain • Personal view and outlook 10.30 Session reserved for Corning Life Sciences Georg Schmitt, Head of Toxicology, Roche Pharmaceuticals David Stresser, Program Manager, Drug Metabolism Services, Corning Life Sciences 4.30 11.10 Morning Coffee • xCELLingence platform (impedance) • Advantages and drawbacks 11.40 Immunogenicity assessment of monoclonal antibodies and The use of label free technologies in drug development • Defining optimal conditions for your cells bio-technology derived therapeutic proteins • Toxicity and pharmacology • Scientific and regulatory considerations on the CASE STUDY • Coupling RTCA with cell imaging immunogenicity of biologics Franck Atienzar, Associate Director, UCB • Comparative review of the EMA vs. FDA guidelines for immunogenicity of biologics development 5.10 Contemporary nonclinical approaches to cardiac safety • A risk based approach to immunogenicity concerns in drug assessment in drug development Adina Tocoian, Senior Clinical Pharmacologist, UCB • Overview of CV data generated in the preclinical space • Reducing attrition: in silico, in vitro, in vivo assessment BIOLOGICS V/S SMALL MOLECULES IN ADMET • Integration of data to inform on pathogenesis • Building an integrated structure/function strategy to CV 12.20 Modulation of drug absorption via internal hydrogen bonding safety • Impact of internal H-bonding on absorption • Prediction of internal H-bonding • Application to drug design Andy McElroy, CEO, EligoChem Ltd Official Media Partners Peter Clements, Director of Pathology, GSK CASE STUDY 5.50 Chairman’s Closing Remarks and Close of Day One Supported by Register online at: www.admet-event.com • Alternatively fax you
ADMET 2014 t-event.com Day Two I Tuesday 1st July 2014 8.30 Registration & Coffee 12.20 Integrating ADME and toxicity data to enhance the prediction and understanding of drug safety in humans 9.00 Chairman’s Opening Remarks • ADME endpoints considered most relevant to drug safety Gerry Kenna, Safety Science Adviser and Network Partner, • Value and limitations of in vivo toxicity assessment The Research Network Ltd • In silico and in vitro toxicity evaluation • Approaches for data integration – the need for 9.10 physiologically based systems models Risk assessment and mitigation strategies for reactive metabolites in drug discovery Gerry Kenna, Safety Science Adviser and Network Partner, The Research Network Ltd • isk factors: drug related and patient related R • Risk assessment and mitigation strategies in the pharmaceutical industry • Idiosyncratic adverse drug reactions: CASE STUDY Multiple contributory mechanisms 1.00 Networking Lunch 2.00 Significance of plasma protein binding for pharmacokinetics and the utility of TRANSIL assays • Case study • Free fraction and equilibrium distribution Richard Thompson, Principal Scientist, AstraZeneca • Binding site affinity, receptor affinity and displacement • Plasma dilution, apparent recovery are absolute recovery 9.50 Experimental strategies to predict [and therefore avoid] • Assay systems for peptide drugs adverse hepatic effects in clinical trials Hinnerk Boriss, CEO, Sovicell • Current challenges in predicting clinical hepatotoxicity UPDATE ON DRUG TRANSPORTERS • Sensitivity, specificity & clinical relevance of experimental models • Differences in the underlying mechanism(s) of hepatic 2.40 Evolving transporter strategies in drug development • Understanding clinically relevant drug transporters and their dysfunction importance in the pharmaceutical industry • Use of emerging technologies like 3D cell culture to predict • Case study at GSK hepatotoxicity • Drug transporter regulatory interactions Chris Powell, VP Safety Assessment, GSK CASE STUDY • Key learnings & application to future projects Sandra Baldwin, In Vitro DMPK Manager, GSK 10.30 Morning Coffee toxicity 3.20 Afternoon Tea 3.50 11.00 Assessing the effectiveness of non-animal models to predict In vivo models for the study of drug transporters • Prediction goals in using computational and in vitro • nimal models available A approaches to assess toxicity - Knockout and transgenic animals • Understanding and evaluating the latest models • elevance and experimental settings R • Predicting end points and future challenges and • ase studies and potential applications C Laurent Salphati, Senior Scientist, Genentech opportunities Alan Boobis, Professor of Biochemical Pharmacology, Imperial College London 4.30 The different roles of drug transporters in research and development • rug and drug metabolites are actively transported into and D IN SILICO AND IN VITRO APPROACHES out of cells by a variety of transporters • ransporters – a view from different angles: determinant of T 11.40 What added value can PBPK bring to drug discovery? PK, PD, efficacy and safety • Overview of PBPK • egulatory guidance, clinical importance and implications R • Possible applications in drug discovery • ow far is ‘IVIVC’ for transporters? H • Case studies Dietmar Weitz, Lab Head/ADME in Vitro Systems, Sanofi-Aventis • Challenges and opportunities Nathalie Gobeau, Metabolism and Pharmacokinetics, Novartis 5.10 Chairman’s Closing Remarks and Close of Day Two Supported by ur registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 Want to know how you can get involved? Interested in promoting your services to this market? Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email firstname.lastname@example.org
HALF-DAY POST-CONFERENCE WORKSHOP A Wednesday 2nd July 2014 I 08.30 – 12.30 I Marriott Regents Park Hotel, London, UK In association with Computational Approaches in ADMET Overview of workshop: About the workshop host: Within the last few years there has been a step-change in the use of computational approaches to examine biological processes. An important challenge is to use these new approaches to better predict drug action (both pharmacology and toxicology) as early in the drug pipeline as possible Dr Nick Plant has nearly 20 years’ experience researching the coordination of cellular responses, which balance the adaptation to altered chemical environments within the body, while maintaining core body functioning. His research has focussed on members of the superfamily of nuclear receptors, which act as ligandactivated transcription factors, sensing their cellular surroundings and coordinating network responses. Utilising both small- and largescale computational approaches his lab aims to understand the coordination of body responses to both external perturbations (e.g. dietary and pharmacological) and during disease progression (e.g. breast cancer), as well as feasibility studies towards the reconstruction of the “silicon human”. This workshop will cover both the theory of these new approaches, and the application of them to a real test case. No previous experience in computational modelling will be assumed! Why you should attend: Computational biology is a rapidly changing field, with new approaches being developed every day. This workshop will help the non-specialist understand what they can expect from such approaches, why these approaches can be applied to ADMET and how they can apply them to their own projects. Note: Practical Session presume that attendees will have access to a PC/tablet and Internet access. Practical Sessions will be run via the network. About The University of Surrey The University of Surrey is a UK top-ten research intensive University based at Guildford, Surrey, UK. Its computational and Systems biology research group is based within the Faculty of Health and Medical Sciences. Programme: 08.30 09.00 09.10 09.50 10.30 11.00 11.40 12.20 Registration and coffee Opening remarks Session 1 Theory of Relational Databases Session 2 Practical Session on Relational Databases Coffee break Session 3 Theory of Constraint-Based Models Session 4 Practical Session on Constraint-Based Models Closing remarks HALF-DAY POST-CONFERENCE WORKSHOP A Wednesday 2nd July 2014 I 13.30 – 17.30 I Marriott Regents Park Hotel, London, UK In association with ADME for the Medicinal Chemist Overview of workshop: The session will begin an overview of the digestive system and relate each organ to its corresponding ADME issue. An interactive workshop will focus on routes of administration. A second session will focus on permeability, Pgp and CYP 450 and will be followed by a workshop where participants will explore the literature to distil working solutions to recurrent medicinal chemistry issues. Why you should attend: Medicinal chemists with up to 5 years in industry. Academics who wish to acquaint themselves with key issues in the drug discovery process. The session is suitable to graduates, PhD and Post Doctoral fellows and assumes no prior knowledge. This workshop is not suitable for scientists already versed in ADME. Programme: 13.30 Registration and coffee 14.00 Opening remarks 14.10 Session 1 ADME – Voyage through the digestive system 14.50 Session 2 Workshop – Routes of dministration & literature a abstraction 15.30 Coffee break 16.00 Session 3 Permeability & Pgp 16.30 Session 4 Liver Metabolism 17.20 Closing remarks 17.30 End of workshop About the workshop hosts: Corinne read Organic Chemistry at Lyon University, France (1984). She then joined Roche (1984-1990) as a medicinal chemist where she was involved in the Trocade as well as the Saquinavir projects. In addition, she played a key role in establishing a Solid Phase Peptide and Oligonucleotide synthesis facility in house. She then Joined Glaxo in 1990, where she has worked on a number of Protease and GPCR drug Discovery projects at various stages of lead discovery and lead optimisation. Corinne then obtained a GlaxoSmithKline sponsored PhD at the University of Cambridge (2000) having worked with Prof S V Ley, FRS on the discovery of novel solid phase amine linkers. She then joined Organon in 2001 where she became responsible for Medicinal Chemistry training of staff and more recently founded Med-Simple, a company specialising in applied Medicinal Chemistry training. She is the author of over 45 publications, book chapters and reviews in these areas. Her research interests include the design of chemical libraries, peptide synthesis, solid phase synthesis and ADME. About the organisation Med-Simple was created in 2004 and provides tailor-made medicinal chemistry courses for the pharmaceutical industry. In the spirit of the company motto is ‘Things should be as simple as they can be’ (A. Einstein) Med-Simple prides itself in delivering complex medicinal chemistry concepts in an easy to digest format. Its trademark ‘Succeed through the li terature approach’, as well as innovative teaching methods have placed the company finalist in the 2012 Small Business Award for Innovation.
Sponsored by Admescope provides innovative contract research services for preclinical ADMETox, from tailor-made assays to HTS-studies. In addition to having comprehensive service portfolio in the field, we are specialized in drug metabolism and drug interaction studies. Currently Admescope serves customers in Europe, USA and Canada, from virtual biotechs to Big Pharma companies. To learn more, please visit www.admescope.com Corning Life Sciences is a global manufacturer of tools and equipment for cell culture, molecular biology, drug discovery and microbiology. Our leading Corning®, Falcon®, Costar®and Gosselin™ brands include vessels and differentiated surfaces for cell culture and scale-up, liquid handling products, ADME/Tox products and services, microbiology consumables and purification kits. www.corning.com/lifesciences SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick, Director on+44 (0) 20 7827 6168 or email: email@example.com Who should attend this conference: Previous Attendee Profile You should attend this event if you are a Chief Executive, Vice President, Head, Director, Chief Scientist, Principal Scientist, Project Leader, Manager from within the Pharmaceutical or Healthcare industry within responsibilities in the following areas: Chief Principle Scientist CEO/Director/Manage Head of Pharmacology/DMPK/Toxicology Professor/Academia Other • ADME • Toxicology • DMPK • PBPK • PD/PK • Computational Modelling and Simulation • Pathology • Computational Chemistry • Computational Toxicology • Pre-clinical Safety • Clinical Pharmacology • Genotoxicity • Drug Metabolism • Regulatory Pharmaco-Toxicology 35% 23% 21% 14% 5% 21% 35% 5% 14% 23% SMi FORWARD PLANNER MARCH APRIL JUNE Superbugs & Superdrugs - A Focus on Antibacterials 5 – 6 March 2014, London Asthma & COPD BioBanking 23 – 24 June 2014, London Imaging in Cancer Drug Development 12 – 13 March 2014, London Controlled Release 12 – 13 March 2014, London Adaptive Designs 24 – 25 March 2014, London Paediatric Clinical Trials 31 March – 1 April 2014, London Pre-Filled Syringes USA 31 March – 1 April 2014, USA 2 – 3 April 2014, London Biosimilars USA 7 – 8 April 2014, USA Peptides 30 June – 1 July 2014, London MAY ADMET 30 June – 1 July 2014, London Big Data in Pharma 12 – 13 May 2014, London JULY Pain Therapeutics 19 – 20 May 2014, London Lyophilisation 7 – 8 July 2014, London ADC Summit 19 – 20 May 2014, London BioNetworks 7 – 8 July 2014, London Clinical Trial Logistics 21 – 22 May 2014, London Allergies 9 – 10 July 2014, London Immunogenicity 14 – 15 July 2014, London
ADMET 2014 Conference: Monday 30th June and Tuesday 1st July 2014 , The Marriott Regents Park Hotel, London, UK I Workshops: Wednesday 2nd July 2014, London 4 WAYS TO REGISTER ONLINE www.admet-event.com FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK EARLY BIRD □ DISCOUNT □ Book by 31st March to receive £300 off the conference price Book by 30th April to receive £100 off the conference price CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Unique Reference Number Our Reference GROUP DISCOUNTS AVAILABLE P-109 DELEGATE DETAILS Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Title: Forename: Surname: Job Title: □ Conference & 2 Workshops □ Conference & 1 Workshop □ Conference only □ 1 Workshop only □ 2 Workshops only Workshop A □ Workshop B □ £2098.00 + VAT £2517.60 £1499.00 + VAT £1798.80 £599.00 Company/Organisation: Email: + VAT £718.80 £1198.00 + VAT £1437.60 PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional literature to all conference attendees £999.00 Department/Division: Total £2697.00 + VAT £3236.40 + VAT £1198.80 The Conference fee includes refreshments, lunch, conference papers and CD ROM containing all of the presentations. Company VAT Number: Address: LIVE STREAMING/ON DEMAND/DOCUMENTATION Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Mobile: Switchboard: Signature: Date: I agree to be bound by SMi’s Terms and Conditions of Booking. ACCOUNTS DEPT Title: Forename: Surname: Unable to travel, but would like to watch the conference live, ask questions, participate as if you were in the room? Price Total □ Live Streaming £999.00 + VAT £1198.80 □ On demand £599.00 + VAT £718.80 (available 24 hours after the event) □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80 □ The Conference Presentations – paper copy 499.00 - £ £499.00 (or only £300 if ordered with the Document Portal) PAYMENT Email: Address (if different from above): Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-109 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: VENUE The Marriott Regents Park Hotel, 128 King Henry’s Rd, London NW3 3ST □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: firstname.lastname@example.org or fax +44 (0) 870 9090 712 Terms and Conditions of Booking Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager email@example.com or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter. □ UK BACS □ Wire Transfer □ Cheque □ Credit Card Sort Code 300009, Account 00936418 Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 We can only accept Sterling cheques drawn on a UK bank. □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Card No: Cardholder’s Name: Signature: Date: I agree to be bound by SMi’s Terms and Conditions of Booking. Card Billing Address (If different from above): VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live Streaming, on Demand, Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at firstname.lastname@example.org
SMi Group’s ADMET conference and exhibition returns to London in June 2016 for its 11th ... Join us at SMi's 11th annual ADMET taking place on the ...
SMi Group's Inaugural Peptides conference. ... MA B £1 B D R Y 00 Y IS CH DI 30 CO SC TH UN O AP T UN R T IL SMi present their inaugural conference on ...
We're trying Google Ads to subsidize server costs. If you are logged in, you won't see ads. Hover to learn more.
Pearl Dark Black_Helmet(M2000) ... 7 to finally fend off Indiana in the Eastern Conference finals this year. a 6 ... singing the group's ...
Chemical Computing Group's ... SBS 11th Annual Conference and Exhibition: ... 9th European Conference on Research and Advanced Technology for Digital ...
View 2102 Admet posts, presentations, experts, and more. Get the professional knowledge you need on LinkedIn. LinkedIn Home What is LinkedIn? Join Today